Bernstein analyst William Pickering initiated coverage of Beam Therapeutics with a Market Perform rating and $37 price target. The analyst has "enthusiasm" for Beam’s technology, but struggles to meet consensus estimates without assuming a significant revenue contribution from future pipeline assets that have not yet been identified. As such, the firm is below consensus on the estimated revenue from sickle cell disease and most Beam’s other assets.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BEAM:
- Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
- Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
- Stifel says SVB fallout ‘appears limited’ across firm’s biotech coverage
- Beam Therapeutics price target lowered to $105 from $125 at Wells Fargo
- Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
